Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder - Full Text View

Sponsored by:	National Institute of Mental Health (NIMH)
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00050050

Purpose

This study will determine the effectiveness of cognitive behavioral therapy (CBT) in treating the symptoms of attention deficit hyperactivity disorder (ADHD) in adults who have not responded to drug treatment.

Study hypothesis: CBT is an effective treatment for adult ADHD.

Condition	Intervention	Phase
Attention Deficit Disorder With Hyperactivity	Behavioral: Cognitive behavioral therapy Drug: Drug therapy	Phase I

MedlinePlus related topics: Attention Deficit Hyperactivity Disorder

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title:	CBT for Residual ADHD Symptoms in Adults

Further study details as provided by National Institute of Mental Health (NIMH):

Primary Outcome Measures:

ADHD symptoms

Estimated Enrollment:	40
Study Start Date:	September 2001
Estimated Study Completion Date:	June 2003

Detailed Description:

ADHD, previously believed to be a disorder of childhood, affects as many as 5 percent of adults. Adults with ADHD are at high risk for academic and occupational underachievement, relationship difficulties, and reduced quality of life. This study will determine whether CBT is more effective than drug therapy in treating ADHD symptoms in adults who have been resistant to previous drug therapies.

Participants will be randomly assigned to receive 12 to 15 weekly sessions of either CBT or drug therapy which may include new or previously taken drugs. Questionnaires will be used to assess participants’ ADHD symptoms at study start and at study completion.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Adult ADHD of at least moderate severity
On current drug therapy for ADHD

Exclusion Criteria:

Depression, panic disorder, bipolar disorder, organic mental disorders, psychotic disorders, or pervasive developmental disorders
Current substance abuse or dependence
IQ less than 90
Suicide risk
History of cognitive behavioral therapy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00050050

Locations

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

Investigators

Principal Investigator:

Steven A. Safren, PhD

Massachusetts General Hospital

More Information

Study ID Numbers:	R03 MH60940, DSIR AT-AS
Study First Received:	November 20, 2002
Last Updated:	November 17, 2005
ClinicalTrials.gov Identifier:	NCT00050050
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):

Adult
ADHD
ADD

Study placed in the following topic categories:

Signs and Symptoms
Attention Deficit Disorder with Hyperactivity
Mental Disorders
Mental Disorders Diagnosed in Childhood

Neurologic Manifestations
Attention Deficit and Disruptive Behavior Disorders
Hyperkinesis
Dyskinesias

Additional relevant MeSH terms:

Pathologic Processes
Disease
Nervous System Diseases

ClinicalTrials.gov processed this record on January 15, 2009